POLICHEMIOTERAPIA PROMCAE-MOPP VS PROMACE-CYTABOM NEL TRATTAMENTO DEI LINFOMI NON-HODGKIN A GRANDI CELLULE E INCLASSIFICABILI

Translated title of the contribution: ProMACE-MOPP vs ProMACE-CytaBOM chemotherapy in the treatment of large cell unclassified non-Hodgkin's lymphomas

C. Pieresca, P. G. Gobbi, D. Bertoloni, G. Grignani, A. Rossi, M. C. Legnani, M. Giordano

Research output: Contribution to journalArticle

Abstract

The results of two distinct and successive clinical pilot studies investigating feasibility of aggressive chemotherapy in large cell and unclassified non-Hodgkin's lymphomas are reported. In the first study (1986-87) the ProMACE-MOPP chemotherapy (P-M), a 2(nd) generation regimen, was administered to 10 patients, whereas in the second study (1987-88) the ProMACE-CytaBOM schedule (P-C), a 3(rd) generation regimen, was administered to 13 patients. The clinical and prognostic features of the two groups of patients were quite comparable, the only difference being the different follow-up times (median: 43 vs 26 months). The number of complete remissions, freedom from relapse and overall survival were slightly better in the P-M group, without a statistically significant difference, despite the longer follow-up time. Hematological toxicity was higher in the P-M study, while gastrointestinal (mucositis, hepatic transitory damage) and neurological toxicity (peripheral neuritis) were somewhat lower. In conclusion, the P-M regimen is worth considering for the treatment of high grade malignant lymphomas, although it was not recently designed and is not widely used at present.

Translated title of the contributionProMACE-MOPP vs ProMACE-CytaBOM chemotherapy in the treatment of large cell unclassified non-Hodgkin's lymphomas
Original languageItalian
Pages (from-to)267-272
Number of pages6
JournalAnnali Italiani di Medicina Interna
Volume6
Issue number3
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'ProMACE-MOPP vs ProMACE-CytaBOM chemotherapy in the treatment of large cell unclassified non-Hodgkin's lymphomas'. Together they form a unique fingerprint.

  • Cite this

    Pieresca, C., Gobbi, P. G., Bertoloni, D., Grignani, G., Rossi, A., Legnani, M. C., & Giordano, M. (1991). POLICHEMIOTERAPIA PROMCAE-MOPP VS PROMACE-CYTABOM NEL TRATTAMENTO DEI LINFOMI NON-HODGKIN A GRANDI CELLULE E INCLASSIFICABILI. Annali Italiani di Medicina Interna, 6(3), 267-272.